Lindsey Rolfe Biography and Net Worth

Insider of Clovis Oncology

Dr. Lindsey Rolfe has served as our Executive Vice President of Clinical Development and Pharmacovigilance and Chief Medical Officer since August 2015. Dr. Rolfe joined Clovis in April 2010 and served as Senior Vice President of Clinical Development until her promotion. Dr. Rolfe has 20 years of drug development experience and previously served in senior oncology development roles at Celgene Corporation, Pharmion Corporation (acquired in 2008), Cambridge Antibody Technology, UCB Inc. and Celltech Group plc. Dr. Rolfe also serves on the board of directors of Atreca, Inc. (NASDAQ: BCEL). Dr. Rolfe qualified in medicine at the University of Edinburgh. She undertook post graduate medical training in London, U.K. and obtained her post-graduate internal medicine qualification as a Member of the Royal College of Physicians (MRCP). She has specialist accreditation in Pharmaceutical Medicine from the U.K. General Medical Council and is a Fellow of the Faculty of Pharmaceutical Medicine.

What is Lindsey Rolfe's net worth?: The estimated net worth of Lindsey Rolfe is at least $0.00 as of November 3rd, 2020. Dr. Rolfe owns 54,746 shares of Clovis Oncology stock worth more than $0 as of April 24th. This net worth estimate does not reflect any other assets that Dr. Rolfe may own. Learn More about Lindsey Rolfe's net worth.
How old is Lindsey Rolfe?: Dr. Rolfe is currently 50 years old. There are 4 older executives and no younger executives at Clovis Oncology. Learn More on Lindsey Rolfe's age.
How do I contact Lindsey Rolfe?: The corporate mailing address for Dr. Rolfe and other Clovis Oncology executives is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. Clovis Oncology can also be reached via phone at 303-625-5000 and via email at [email protected]. Learn More on Lindsey Rolfe's contact information.
Has Lindsey Rolfe been buying or selling shares of Clovis Oncology?: Lindsey Rolfe has not been actively trading shares of Clovis Oncology over the course of the past ninety days. Most recently, Lindsey Rolfe sold 4,514 shares of the business's stock in a transaction on Wednesday, February 2nd. The shares were sold at an average price of $1.94, for a transaction totalling $8,757.16. Learn More on Lindsey Rolfe's trading history.
Who are Clovis Oncology's active insiders?: Clovis Oncology's insider roster includes Paul Gross (Insider), Thomas Harding (Insider), Gillian Ivers-Read (Insider), and Lindsey Rolfe (Insider). Learn More on Clovis Oncology's active insiders.

Lindsey Rolfe Insider Trading History at Clovis Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/2/2022	Sell	4,514	$1.94	$8,757.16
12/2/2021	Sell	346	$3.00	$1,038.00
11/3/2020	Sell	1,920	$4.93	$9,465.60	54,746
9/21/2020	Sell	1,747	$6.85	$11,966.95	52,744
6/22/2020	Sell	1,728	$6.74	$11,646.72	48,500
6/20/2019	Sell	1,728	$14.70	$25,401.60	23,319
3/20/2019	Sell	1,729	$26.13	$45,178.77	20,953
3/5/2019	Sell	1,731	$29.29	$50,700.99	16,497
12/20/2018	Sell	1,728	$17.72	$30,620.16	17,600
12/4/2018	Sell	284	$21.23	$6,029.32	14,446
10/28/2015	Sell	4,000	$98.02	$392,080.00
10/5/2015	Sell	4,000	$93.04	$372,160.00

Lindsey Rolfe Buying and Selling Activity at Clovis Oncology

Clovis Oncology Company Overview

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Today's Range

Now: N/A

50 Day Range

MA: $0.43

$0.08

$1.09

2 Week Range

Now: N/A

Volume

1,155,888 shs

Average Volume

8,875,886 shs

Market Capitalization

$11.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

Click here now for the full details of this stock that’s set to rocket in the AI revolution…